Atesidorsen

Drug Profile

Atesidorsen

Alternative Names: ATL-1103; COR-004

Latest Information Update: 29 Mar 2016

Price : $50

At a glance

  • Originator Isis Pharmaceuticals
  • Developer Antisense Therapeutics
  • Class Antisense oligonucleotides
  • Mechanism of Action Somatotropin receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Acromegaly
  • Preclinical Cancer; Diabetic retinopathy

Most Recent Events

  • 11 Mar 2016 ALT 1103 is no longer licensed to Strongbridge Biopharma in the World
  • 11 Mar 2016 Strongbridge Biopharma applies for Orphan Drug status in Acromegaly in USA and European Union before March 2016
  • 18 Dec 2015 Isis Pharmaceuticals is now called Ionis Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top